Clinical Trials
11 trialsNCT07060807 2026-06-01
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07022483 2026-05-28
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT06819007 2026-05-26
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT06467357 2026-05-14
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT06764875 2026-05-12
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 3 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT05950945 2026-04-08
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT06899126 2026-01-08
DESTINY-Lung06
Daiichi Sankyo
Phase 3 Recruiting
NCT06174987 2025-10-15
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo
Phase 3 Recruiting
NCT06643585 2025-05-02
SURVIVE HERoes
University of Ulm
Phase 3 Recruiting